The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.00
Bid: 22.00
Ask: 26.00
Change: 0.00 (0.00%)
Spread: 4.00 (18.182%)
Open: 24.00
High: 0.00
Low: 0.00
Prev. Close: 24.00
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

10 Nov 2023 10:14

RNS Number : 0964T
Oncimmune Holdings PLC
10 November 2023
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BYQ94H38

Issuer Name

ONCIMMUNE HOLDINGS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Spreadex LTD

City of registered office (if applicable)

St. Albans

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

08-Nov-2023

6. Date on which Issuer notified

09-Nov-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

2.485800

3.665100

6.150900

4560383

Position of previous notification (if applicable)

1.926100

4.049200

5.975300

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BYQ94H38

1843032

2.485800

Sub Total 8.A

1843032

2.485800%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

CFD/Spreadbet

2717351

3.665100

Sub Total 8.B1

2717351

3.665100%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

09-Nov-2023

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBMBMTMTBBBJJ
Date   Source Headline
28th Jan 20207:00 amRNSLung Test More Cost Effective Compared to CT
27th Jan 20207:00 amRNSNotice of Capital Markets Update
23rd Jan 202012:30 pmRNSConsortium of Liver Cancer Industry Leaders
7th Jan 20207:00 amRNSNotice of Half Year Results
7th Jan 20207:00 amRNSChange of Registered Address
12th Dec 20192:07 pmRNSWinner of BioNewsRound Award
29th Nov 20199:58 amRNSResults of Annual General Meeting
4th Nov 20192:46 pmRNSNotice of AGM and Posting of Annual Report
4th Nov 20197:00 amRNSDraw down of second tranche of credit facility
1st Nov 20197:10 amRNSOncimmune and Biodesix seal deal
31st Oct 20197:00 amRNSFinal Results
25th Oct 20197:00 amRNSNotice of Full Year Results ended May 2019
16th Oct 20195:01 pmRNSOncimmune welcomes NHS review of cancer screenings
23rd Sep 20197:00 amRNSKey appointments to further strengthen management
20th Sep 20192:32 pmRNSAppointment of Joint Broker
20th Sep 20197:00 amRNSEUR8.5m Credit Facility Secured
18th Sep 20197:00 amRNSOncimmune to Present at 2019 CBIIC
9th Sep 20197:30 amRNSPositive Results for ECLS Trial Presentation
3rd Sep 201912:00 pmRNSECLS at 2019 World Conference for Lung Cancer
1st Aug 201912:00 pmRNSSolebury Trout European Biotech Investor Day
15th Jul 20197:00 amRNSFurther Expansion in Spain for EarlyCDT Lung
4th Jul 201910:38 amRNSCommercialisation Partnership in Russia
2nd Jul 20197:00 amRNSProactive Investors One2One Investor Forum
28th Jun 20197:00 amRNSCommercialisation Agreement in US with Biodesix
26th Jun 20197:00 amRNSBusiness Update
4th Jun 20197:00 amRNSPositive Results for Early Cancer Detection Test
15th May 20197:00 amRNSRegulatory Approval in Israel for EarlyCDT®-Lung
10th May 20197:00 amRNSInitiation of a Multi-Centre Trial in China
17th Apr 20197:00 amRNSHolding(s) in Company
5th Apr 20197:00 amRNSAgreement for Portugal and Spain
2nd Apr 20197:00 amRNSAppointment of Parag Mallick to Scientific Board
1st Apr 20195:19 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSEarlyCDT®-Lung Registered in Columbia
25th Mar 20197:00 amRNSSpanish Private Hospital to Sell EarlyCDT®-Lung
19th Mar 20197:00 amRNSOncimmune acquires Protagen Diagnostics AG
13th Feb 20197:00 amRNSHalf Year Results
31st Jan 20197:00 amRNSNotice of Half Year Results
24th Jan 20197:00 amRNSGrant of Options and PDMR notification
23rd Jan 20197:00 amRNSOncimmune to host Science Day in London today
14th Jan 20197:00 amRNSOncimmune Science Day
20th Dec 20182:13 pmRNSOncimmune signs US distribution agreement
13th Dec 20187:00 amRNSOncimmune appoints new Scientific Board
6th Dec 20184:34 pmRNSSenior Leadership Team Appointments & Board Change
30th Nov 201810:46 amRNSResult of AGM
28th Nov 20187:10 amRNSDistribution Agreements & Registration Outside EU
5th Nov 20187:00 amRNSAnnual Report and Accounts and AGM Notification
31st Oct 20187:00 amRNSResults for the year ended 31 May 2018
1st Oct 20187:00 amRNSBusiness Update
28th Sep 20187:00 amRNSAppointment of Non-Executive Director
25th Sep 20183:45 pmRNSIASLC World Conference on Lung Cancer Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.